Drug
Octreotide (drug)
Octreotide (drug) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
25%
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Not yet recruiting2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
not_yet_recruiting250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
NCT07460908
not_yet_recruitingphase_1
Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
NCT06881888
not_yet_recruitingphase_4
Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
NCT06974344
completedphase_3
Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia
NCT00804297
Clinical Trials (4)
Showing 4 of 4 trials
NCT07460908Not Applicable
Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome
NCT06881888Phase 1
Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
NCT06974344Phase 4
Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
NCT00804297Phase 3
Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4